FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1999042332> ?p ?o ?g. }

• W1999042332 endingPage "1495" @default.
• W1999042332 startingPage "1485" @default.
• W1999042332 abstract "Purpose Loss of the cell-cycle regulatory protein p53 or overexpression of the antiapoptotic protein Bcl-2 is associated with resistance to radiation in several types of cancer cells. Flavopiridol, a synthetic flavone, inhibits the growth of malignant tumors cells in vitro and in vivo through multiple mechanisms. The purpose of the present study is to clarify whether flavopiridol enhances the cytotoxic effects of radiation in tumor cells that contain dysfunction p53 or that overexpress Bcl-2. Methods and Materials A human glioma cell line (A172/mp53) stably transfected with a plasmid containing mutated p53 and a human cervical cancer cell line (HeLa/bcl-2) transfected with a bcl-2 expression plasmid were used. Cells were incubated with flavopiridol for 24 h after radiation, and then cell viability was determined by a colony formation assay. Foci of phosphorylated histone H2AX were also evaluated as a sensitive indicator of DNA double-strand breaks. Results Compared with the parental wild-type cells, both transfected cell lines were more resistant to radiation. Post-treatment with flavopiridol increased the cytotoxic effects of radiation in both transfected cell lines, but not in their parental wild-type cell lines. Post-treatment with flavopiridol inhibited sublethal damage repair as well as the repair of DNA double-strand breaks in response to radiation. Conclusions Flavopiridol enhanced the cytotoxic effect of radiation in radioresistant tumor cells that harbor p53 dysfunction or Bcl-2 overexpression. A combination treatment of flavopiridol with radiation has the potential to conquer the radioresistance of malignant tumors induced by the genetic alteration of p53 or bcl-2. Loss of the cell-cycle regulatory protein p53 or overexpression of the antiapoptotic protein Bcl-2 is associated with resistance to radiation in several types of cancer cells. Flavopiridol, a synthetic flavone, inhibits the growth of malignant tumors cells in vitro and in vivo through multiple mechanisms. The purpose of the present study is to clarify whether flavopiridol enhances the cytotoxic effects of radiation in tumor cells that contain dysfunction p53 or that overexpress Bcl-2. A human glioma cell line (A172/mp53) stably transfected with a plasmid containing mutated p53 and a human cervical cancer cell line (HeLa/bcl-2) transfected with a bcl-2 expression plasmid were used. Cells were incubated with flavopiridol for 24 h after radiation, and then cell viability was determined by a colony formation assay. Foci of phosphorylated histone H2AX were also evaluated as a sensitive indicator of DNA double-strand breaks. Compared with the parental wild-type cells, both transfected cell lines were more resistant to radiation. Post-treatment with flavopiridol increased the cytotoxic effects of radiation in both transfected cell lines, but not in their parental wild-type cell lines. Post-treatment with flavopiridol inhibited sublethal damage repair as well as the repair of DNA double-strand breaks in response to radiation. Flavopiridol enhanced the cytotoxic effect of radiation in radioresistant tumor cells that harbor p53 dysfunction or Bcl-2 overexpression. A combination treatment of flavopiridol with radiation has the potential to conquer the radioresistance of malignant tumors induced by the genetic alteration of p53 or bcl-2." @default.
• W1999042332 created "2016-06-24" @default.
• W1999042332 creator A5004288177 @default.
• W1999042332 creator A5064548129 @default.
• W1999042332 creator A5076625974 @default.
• W1999042332 creator A5083301071 @default.
• W1999042332 creator A5090500928 @default.
• W1999042332 date "2008-08-01" @default.
• W1999042332 modified "2023-10-02" @default.
• W1999042332 title "Flavopiridol Potentiates the Cytotoxic Effects of Radiation in Radioresistant Tumor Cells in Which p53 is Mutated or Bcl-2 is Overexpressed" @default.
• W1999042332 cites W1515564094 @default.
• W1999042332 cites W1972559902 @default.
• W1999042332 cites W1986509532 @default.
• W1999042332 cites W1987484894 @default.
• W1999042332 cites W1996111467 @default.
• W1999042332 cites W2002938475 @default.
• W1999042332 cites W2005479501 @default.
• W1999042332 cites W2019133865 @default.
• W1999042332 cites W2038894733 @default.
• W1999042332 cites W2039029991 @default.
• W1999042332 cites W2039639418 @default.
• W1999042332 cites W2047277968 @default.
• W1999042332 cites W2055078984 @default.
• W1999042332 cites W2061414735 @default.
• W1999042332 cites W2063530367 @default.
• W1999042332 cites W2066107979 @default.
• W1999042332 cites W2070148684 @default.
• W1999042332 cites W2123255647 @default.
• W1999042332 cites W2129581056 @default.
• W1999042332 cites W2154994717 @default.
• W1999042332 cites W2323231231 @default.
• W1999042332 cites W4321429133 @default.
• W1999042332 doi "https://doi.org/10.1016/j.ijrobp.2008.03.039" @default.
• W1999042332 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18640498" @default.
• W1999042332 hasPublicationYear "2008" @default.
• W1999042332 type Work @default.
• W1999042332 sameAs 1999042332 @default.
• W1999042332 citedByCount "37" @default.
• W1999042332 countsByYear W19990423322012 @default.
• W1999042332 countsByYear W19990423322013 @default.
• W1999042332 countsByYear W19990423322014 @default.
• W1999042332 countsByYear W19990423322015 @default.
• W1999042332 countsByYear W19990423322016 @default.
• W1999042332 countsByYear W19990423322017 @default.
• W1999042332 countsByYear W19990423322018 @default.
• W1999042332 countsByYear W19990423322019 @default.
• W1999042332 countsByYear W19990423322021 @default.
• W1999042332 countsByYear W19990423322022 @default.
• W1999042332 countsByYear W19990423322023 @default.
• W1999042332 crossrefType "journal-article" @default.
• W1999042332 hasAuthorship W1999042332A5004288177 @default.
• W1999042332 hasAuthorship W1999042332A5064548129 @default.
• W1999042332 hasAuthorship W1999042332A5076625974 @default.
• W1999042332 hasAuthorship W1999042332A5083301071 @default.
• W1999042332 hasAuthorship W1999042332A5090500928 @default.
• W1999042332 hasConcept C105696609 @default.
• W1999042332 hasConcept C111337013 @default.
• W1999042332 hasConcept C121332964 @default.
• W1999042332 hasConcept C126322002 @default.
• W1999042332 hasConcept C134935766 @default.
• W1999042332 hasConcept C143425029 @default.
• W1999042332 hasConcept C1491633281 @default.
• W1999042332 hasConcept C153911025 @default.
• W1999042332 hasConcept C154317977 @default.
• W1999042332 hasConcept C185544564 @default.
• W1999042332 hasConcept C202751555 @default.
• W1999042332 hasConcept C206684579 @default.
• W1999042332 hasConcept C26114605 @default.
• W1999042332 hasConcept C2777366897 @default.
• W1999042332 hasConcept C29537977 @default.
• W1999042332 hasConcept C502942594 @default.
• W1999042332 hasConcept C509974204 @default.
• W1999042332 hasConcept C53227056 @default.
• W1999042332 hasConcept C54009773 @default.
• W1999042332 hasConcept C54355233 @default.
• W1999042332 hasConcept C552990157 @default.
• W1999042332 hasConcept C58962609 @default.
• W1999042332 hasConcept C71924100 @default.
• W1999042332 hasConcept C81885089 @default.
• W1999042332 hasConcept C86803240 @default.
• W1999042332 hasConceptScore W1999042332C105696609 @default.
• W1999042332 hasConceptScore W1999042332C111337013 @default.
• W1999042332 hasConceptScore W1999042332C121332964 @default.
• W1999042332 hasConceptScore W1999042332C126322002 @default.
• W1999042332 hasConceptScore W1999042332C134935766 @default.
• W1999042332 hasConceptScore W1999042332C143425029 @default.
• W1999042332 hasConceptScore W1999042332C1491633281 @default.
• W1999042332 hasConceptScore W1999042332C153911025 @default.
• W1999042332 hasConceptScore W1999042332C154317977 @default.
• W1999042332 hasConceptScore W1999042332C185544564 @default.
• W1999042332 hasConceptScore W1999042332C202751555 @default.
• W1999042332 hasConceptScore W1999042332C206684579 @default.
• W1999042332 hasConceptScore W1999042332C26114605 @default.
• W1999042332 hasConceptScore W1999042332C2777366897 @default.
• W1999042332 hasConceptScore W1999042332C29537977 @default.
• W1999042332 hasConceptScore W1999042332C502942594 @default.
• W1999042332 hasConceptScore W1999042332C509974204 @default.
• W1999042332 hasConceptScore W1999042332C53227056 @default.

• next